PT-141
Bremelanotide · Vyleesi
FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, with off-label research in men.
Half-Life
~2.7 hours
MW
1025.2 Da
Amino Acids
7 AA
Evidence
High Evidence
Regulatory Status
FDA-approved (Vyleesi) for HSDD in premenopausal women. Research for male sexual dysfunction.
In Plain English
Works in the brain — not in blood vessels like Viagra — to trigger sexual arousal. Activates melanocortin receptors in the hypothalamus to increase desire and arousal centrally. FDA-approved (Vyleesi) for low sexual desire in women.
Overview
PT-141 (Bremelanotide, Vyleesi) is a cyclic heptapeptide melanocortin receptor agonist. The first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally (brain) to increase sexual desire rather than peripherally like PDE5 inhibitors.
Common Formats
- Auto-injector pen (approved)
- Lyophilized powder (compounded/research)
Storage Notes
Refrigerate 2-8°C.
Looking for multi-compound protocols?
Browse educational protocol discussions that include PT-141.
Related Compounds
Kisspeptin
An endogenous neuropeptide and master regulator of the HPG axis, GnRH release, and reproductive function with significant clinical research interest.
Melanotan II
A cyclic alpha-MSH analogue with potent melanogenic, sexual arousal, and appetite-suppressing effects through broad melanocortin receptor activation.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.